Higher Tacrolimus Blood Concentration is Related to Increased Risk of Post-Transplantation Diabetes Mellitus after Living Donor Liver Transplantation

Jiu-lin Song,Ming Li,Lu-Nan Yan,Jia-Yin Yang,Jian Yang,Li Jiang
DOI: https://doi.org/10.1016/j.ijsu.2017.12.037
2018-01-01
International Journal of Surgery
Abstract:Background/Aims: To investigate the association between tacrolimus (TAC) blood concentration and the risk of post-transplantation diabetes mellitus (PTDM) development after living donor liver transplantation (LDLT). Methods: This study reviewed the clinical data of 158 adult LDLT recipients. A cut-off of mean trough concentration of TAC (cTAC) value at the sixth month postoperatively was identified using a receptor operating characteristic curve. Other clinical complications rates were compared between different cTAC groups. Results: Thirty-four (21.5%) recipients developed PTDM during follow-up period. Recipients with PTDM suffered lower 1-, 5- and 10-year overall survival rates (85.2%, 64.9%, and 55.6% vs 92.4%, 81.4%, and 79.1%, p < 0.05) and allograft survival rates (87.9%, 76.9%, and 65.9% vs 94.1%, 88.5%, and 86.0%, p < 0.05) than those without PTDM. The best cut-off value of mean cTAC was 5.9 ng/mL. Recipients with higher cTAC (> 5.9 ng/mL) were more likely to develop hyperlipidemia (39.6% vs 21.9%, p < 0.05), cardio-cerebral events (7.5% vs1.0%, p < 0.05), and infections (37.7% vs19.0%, p < 0.05) than recipients exposed to low cTAC (<= 5.9 ng/mL). However, the two groups showed no difference in the incidence of acute and chronic rejection. Conclusion: Higher mean cTAC at the sixth month postoperatively is related to increased risk of PTDM in LDLT recipients.
What problem does this paper attempt to address?